ClinicalTrials.gg
RecruitingNCT04880356Updated Nov 6, 2026

Longitudinal Study of Ultra-rare Inherited Metabolic and Degenerative Neurological Diseases.

An observational study in Inherited Disease, Rare Diseases and Metabolic Disease, sponsored by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Observational

How we know

From the registry’s dates

  • Started Mar 2021; still recruiting 5 years 8 months later.
Updated Nov 6, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 65 studies in Genetic Diseases, Inborn with a site in Italy — 22 open to participants now, 26 under way, 7 of them phase 3. Genetic Diseases, Inborn · Italy.

Planned enrollment
13th of 19
100 · median 200
Started
2021
with 7 others
Observational
19 of 65
12 open now
Primary completion
2031-03
later than 18 of 25 live
Registered
38th of 65
by date

Among the 65 studies in Genetic Diseases, Inborn with a site in Italy, this one is the 13th largest by planned enrollment of the 19 observational ones that give a count, is one of 8 that started in 2021, is one of 19 observational ones, reaches primary completion later than 18 of the 25 other live ones, and was the 38th registered.

Genetic Diseases, Inborn

585 studies on the registry are indexed under Genetic Diseases, Inborn; 159 are open to participants now.

Browse Genetic Diseases, Inborn studies →

Open to participants now

22 of the 65 studies in Genetic Diseases, Inborn with a site in Italy are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 121 Genetic Diseases, Inborn studies recruiting now, 60 (50%) set no upper age limit and 46 (38%) stop at 75 or younger; 86 take children under 18; 28 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Genetic Diseases, Inborn with a site in Italy, or all of them as a file.
02

Study summary

General aim of the study is the improvement of the clinical knowledge of ultra-rare inherited metabolic and degenerative neurological diseases (prevalence less than 5:100,000) in adulthood through the systematic longitudinal collection of clinical, laboratory and instrumental data.

Read the detailed description

The study provides a collection of retrospective data from adult patients with ultra-rare inherited neurological diseases followed at "Carlo Besta" Neurological Institute from 1st January 2004 until March 2021. Further, prospective data will be collected starting from March 2021 (date of protocol approval) and spanning the next ten years. Normal clinical practice will be followed for collection of the prospective data. Follow-up assessment will be performed at least once a year to evaluate the disease course. Based on their clinical manifestations, patients will be assessed by using quantitative functional tests (clinimetric tests such as Timed Up and Go Test) and traditional ordinal scales (such as the scale for the assessment and rating of ataxia (SARA). Moreover, a varying of laboratory and instrumental tests (e.g., neuroimaging, neurophysiological investigations, etc.) will be used according to clinical practice in selected patients.

03

Conditions studied

  • Inherited Disease
  • Rare Diseases
  • Metabolic Disease
  • Undiagnosed Disease
  • Neurologic Disorder
  • Neuro-Degenerative Disease

Keywords

  • Leukodystrophies,
  • Adrenoleukodystrophy,
  • Metachromatic leukodystrophy,
  • Krabbe disease,
  • Vanishing White Matter Syndrome,
  • Alexander disease,
  • Hereditary Leukodystrophy with Spheroids (CSF1R-related HLDS),
  • Nasu-Hakola disease (TREM2- and TYROBP-related disease)
  • Leukoencephalopathy, progressive, with ovarian failure (LKENP, AARS2-related),
  • Pelizaeus-Merzbacher disease,
  • Pelizaeus-Merzbacher-like disease,
  • Hypomyelinating leukodystrophies,
  • Leukodystrophies with calcifications and cysts (LCC),
  • Leukoencephalopathy with ataxia disease (LKPAT, CLCN2-related),
  • L-2-Hydroxyglutaric aciduria,
  • Polyglucosan bodies disease,
  • Methylmalonic acidemia with homocystinuria,
  • Niemann-pick type C,
  • Fahr's disease,
  • Wilson's disease,
  • Cerebrotendinous Xanthomatosis,
  • Sphingolipidoses
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with ultra-rare inherited degenerative and metabolic neurological diseases

Adults with undiagnosed neurological diseases (when supposed to be inherited)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >= 18 years
  • Subjects with ultra-rare inherited degenerative and metabolic neurological diseases
  • Subjects with undiagnosed neurological diseases (when supposed to be inherited)

Exclusion criteria

Exclusion Criteria:

  • none
05

Study design

Observational model
Other
Time perspective
Other
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Retrospective study

    collection of retrospective data from adult patients with ultra-rare inherited neurological diseases

    Other: collection of data

  • Prospective study

    prospective data will be collected starting from March 2021 (date of protocol approval) and spanning the next ten years

    Other: collection of data

Interventions

  • Othercollection of data

    collection of retrospective and prospective data from adult patients with ultra-rare inherited neurological diseases

06

What researchers measure

Primary outcomes

  1. Verbal (letter) fluency

    Repeated Montreal Cognitive Assessment (MoCA) letter F fluency subtest

    Time frame: 10 years

  2. Stance and gait performances [Time Frame: 10 years] Stance and gait performances

    Repeated SARA (Scale for the Assessment and Rating Ataxia) stance subtask, ambulation index (AI) and Timed Up and Go (TUG) test

    Time frame: 10 years

  3. Upper limb motor function

    Repeated ONLS (Overall Neuropathy Limitation Scale) arm scale

    Time frame: 10 years

  4. Swallowing function (dysphagia)

    Repeated NP-C mDRS (Niemann-Pick type C modified disability rating scale) swallowing scale

    Time frame: 10 years

  5. Speech function (dysarthria)

    Repeated NP-C mDRS language scale

    Time frame: 10 years

  6. Bladder function

    Repeated AADS (Adult Adrenoleukodystrophy Disability Score) Bladder function scale

    Time frame: 10 years

  7. Sleep

    Repeated assessment of presence or absence of sleep disturbances

    Time frame: 10 years

  8. Quality of life

    Repeated EuroQol-5D-5L (EQ-5D-5L) questionnaire

    Time frame: 10 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Benzoni C, Moscatelli M, Lanteri P, Pensato V, Calo C, Allievi S, Gellera C, Ardissone A, Moroni I, Fenu S, Cavalca E, Pareyson D, Salsano E. Adrenoleukodystrophy in adults: phenotypic characterisation and natural history in a large cohort. J Neurol Neurosurg Psychiatry. 2026 May 14;97(6):483-492. doi: 10.1136/jnnp-2025-337540. PubMed 41667276 ↗
  • Moscatelli M, Benzoni C, Doniselli FM, Verri M, Pascuzzo R, Aquino D, Mazzi F, Erbetta A, Salsano E. Interval between contrast administration and T1-weighted MRI for cerebral adrenoleukodystrophy: a single-case observation. Eur Radiol Exp. 2023 Oct 2;7(1):57. doi: 10.1186/s41747-023-00373-6. PubMed 37782421 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Mar 2031, 120 months after the start.

Of 94 non-industry observational studies under Genetic Diseases, Inborn, half reached primary completion within 124 months of starting (the median), counting those still running; a quarter within 46. This study's planned 120 months is close to that.

Counting every sponsor, half of 128 studies reached it within 110 months; a quarter within 46 and three quarters within 193.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2021
First posted
May 10, 2021
StartActual
Mar 1, 2021
Primary completionEst.
Mar 2031
CompletionEst.
Mar 2031
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Fondazione IRCCS Istituto Neurologico Carlo Besta · Milan, Italy
Show 1 removed
  • Fondazione IRCCS Istituto Neurologico Carlo Besta · Milano, Italy
Nov 6, 2026
Publications
2 publications citing this study linked from PubMed, e.g. PubMed 41667276 ↗
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Publications 2 publications citing this study linked from PubMed, e.g. PubMed 41667276 ↗
    1 site added, 1 site removed
    Show site
    • Fondazione IRCCS Istituto Neurologico Carlo Besta · Milan, Italy
    Show 1 removed
    • Fondazione IRCCS Istituto Neurologico Carlo Besta · Milano, Italy
    + 4 other changes: index terms, identifiers, verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04880356
Lead sponsor
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Responsible party
Sponsor
First posted
May 10, 2021
Start date
Mar 1, 2021
Primary completion
Mar 2031 (estimated)
Completion
Mar 2031 (estimated)
Last update
Nov 6, 2026

Study contacts

Ettore Salsano, MD
Contact
ettore.salsano@istituto-besta.it
+39022394 ext. 3001
Renato Mantegazza, MD
Contact
crc@istituto-besta.it
+39022394 ext. 2321

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion